NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes Insipidus (NDI).
The genesis of this technology began with Drs. Jeff Sands and Janet Klein, recognized clinical and research leaders in kidney diseases. While NDI patients are now living longer lives with fewer cognitive deficits, the quality of their lives remains diminished. Drs. Sand and Klein were inve...
NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes Insipidus (NDI).
The genesis of this technology began with Drs. Jeff Sands and Janet Klein, recognized clinical and research leaders in kidney diseases. While NDI patients are now living longer lives with fewer cognitive deficits, the quality of their lives remains diminished. Drs. Sand and Klein were investigating the role of AMPK activators as a promising potential therapy to reduce urine volume in NDI patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.